1. Introduction {#sec1}
===============

Thyroid cancer is the most common type of endocrine malignancy, which accounts for nearly 3% of all malignancies \[[@B1]\]. Despite low mortality rate, rates of local recurrence and distant metastases are high in thyroid cancer patients. The incidence of thyroid cancer has been increasing worldwide for the last five years, while the etiology remains largely unknown. Ionizing radiation is a well documented risk factor for thyroid cancer \[[@B2]\]. However, not all individuals exposed to radiation develop this disease, implicating some other unknown factors involved in thyroid carcinogenesis, such as hormone-related factors.

Gender discrepancy is well known in thyroid malignancies. Thyroid cancer occurs three times more frequently in women than in men, and the incidence decreases among postmenopausal women. It has been well established that female sex hormones, particularly estrogens, can influence the proliferation and invasion of thyroid cancer cells by recognizing corresponding hormonal receptors expressed in those cells, such as estrogen receptor alpha and beta \[[@B3]--[@B5]\]. It has been demonstrated that the secretion of thyroid stimulating hormone (TSH) increased during puberty, pregnancy, and oral contraceptive use \[[@B6]\]. Elevated TSH production can promote thyroid growth, while estrogens increase levels of TSH in human body \[[@B7]\]. Therefore, regulation between TSH and estrogens may play a critical role in the development of thyroid disease, thyroid malignancies in particular. Taken together, it can be hypothesized that some hormonal and reproductive factors may confer modifying effects on thyroid carcinogenesis by influencing the signaling of sex hormones and their receptors in thyroid gland. Many epidemiological studies have investigated roles of hormonal and reproductive factors in the development of thyroid cancer, for instance, oral contraceptive use, hormone replacement therapy, menstrual factors, and fertility status \[[@B8]--[@B32]\]. Nevertheless, the precise association has not yet been fully elucidated due to conflicting and inconclusive findings in previous studies. We performed this meta-analysis by pooling all currently published studies to obtain a better estimation and provide important insights into the etiology of thyroid cancer.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We searched studies on the association between hormonal and reproductive factors and thyroid cancer risk in PubMed and Embase databases from their inception up to September 10, 2014, using the following items: thyroid cancer, or thyroid carcinoma; and oral contraceptive, hormone replacement therapy, reproductive factors, menstrual factors, age at menarche, age at first birth, menopausal status, age at menopause, parity, pregnancy, reproductive history, or breast feeding; and incidence, or risk factor. References of relevant studies were also screened for additional papers. If studies were duplicated, only the most complete study was included.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

The included studies must conform to the following inclusion criteria: (1) studies on the association of hormonal and reproductive factors with thyroid cancer risk; (2) cohort or case-control studies; (3) publications presenting odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) with 95% confidence intervals (95% CIs). Studies not associated with hormonal and reproductive factors and thyroid cancer risk, case-only, animal research, case reports, and duplicated studies were all excluded.

2.3. Data Extraction {#sec2.3}
--------------------

Two investigators independently extracted data from each study by use of the following terms: name of first author, year of publication, study design, country of origins, sample size, study period, matching or adjusted factors, and RRs or HRs or ORs with 95% CIs for the estimation of thyroid cancer risk related to hormonal and reproductive factors. Disagreements were solved by discussion.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Roles of hormonal and reproductive factors in thyroid cancer risk were assessed by calculating pooled RRs with 95% CIs by use of STATA 12.0 software (StataCorp, College Station, TX, USA). *P* \< 0.05 was suggested to be statistically significant. The between-study heterogeneity was estimated by Cochran\'s *Q* and *I* ^2^ tests, and *P* \< 0.05 and *I* ^2^ \> 50% implicated obvious between-study heterogeneity \[[@B33], [@B34]\]. The random-effects model was used when the between-study heterogeneity was significant \[[@B35]\]; otherwise, the fixed-effects model was adopted \[[@B36]\]. Stratified analysis by study design (cohort studies, population-based case-control studies, and hospital-based case-control studies) was also performed. Sensitivity analysis by omission of each study was conducted for further analysis. Publication bias risk was evaluated by both Begg\'s funnel plots and Egger\'s test \[[@B37], [@B38]\].

3. Results {#sec3}
==========

3.1. Identification and Characteristics of Studies Included into the Meta-Analysis {#sec3.1}
----------------------------------------------------------------------------------

112 studies were retrieved after a comprehensive literature in databases of PubMed and Embase. However, 87 studies were excluded due to irrelevance, reviews, animal research, and case reports. 25 independent studies on the association between hormonal and reproductive factors and thyroid cancer risk were finally included into our study \[[@B8]--[@B32]\]. Among the 25 studies, 13 were cohort studies, 10 were population-based case-control studies, and the other 2 were hospital-based case-control studies. Characteristics of all included studies were summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Association between Hormonal Factors and Thyroid Cancer Risk {#sec3.2}
-----------------------------------------------------------------

The common hormonal factors including oral contraceptive and hormone replacement therapy did not modify the risk of thyroid cancer (for oral contraceptive: RR = 0.94, 95% CI 0.85--1.04, *P* = 0.215; for hormone replacement therapy: RR = 1.04, 95% CI 0.91--1.19, *P* = 0.527) ([Table 2](#tab2){ref-type="table"}). Sensitivity analysis by sequential omission of each study confirmed the findings (data not shown).

Stratified analysis by study design showed that no significant relationship was observed between hormonal factors and thyroid cancer risk in cohort studies and studies in population-based case-control design ([Table 2](#tab2){ref-type="table"}). We failed to perform stratified analysis in hospital-based case-control studies because of insufficient published studies.

3.3. Association between Reproductive Factors and Thyroid Cancer Risk {#sec3.3}
---------------------------------------------------------------------

The pooled RRs revealed that older age at menopause was associated with weakly increased risk of thyroid cancer in overall analysis (RR = 1.24, 95% CI 1.00--1.53, *P* = 0.049) ([Table 2](#tab2){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}), whereas longer duration of breast feeding was related to moderately reduced risk of thyroid cancer in cohort studies (RR = 0.7, 95% CI 0.51--0.95, *P* = 0.021) ([Table 2](#tab2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). Stratified analysis in hospital-based case-control studies showed that more parity could increase the risk of thyroid cancer (RR = 2.30, 95% CI 1.31--4.04, *P* = 0.004) ([Table 2](#tab2){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}). No significant relationship was observed between thyroid cancer risk and other common reproductive factors ([Table 2](#tab2){ref-type="table"}). Sensitivity analysis did not materially alter the pooled results (data not shown).

3.4. Heterogeneity Analysis and Publication Bias Risk {#sec3.4}
-----------------------------------------------------

No significant between-study heterogeneity was found in most comparisons of overall and stratified analyses, except for the estimation of parity\'s effect on thyroid cancer risk (*I* ^2^ = 61.2%, *P* \< 0.001). Stratified analysis by study design suggested that the main source of between-study heterogeneity resulted from studies in cohort design (*I* ^2^ = 70.6%, *P* \< 0.001).

As suggested by Begg\'s funnel plots and Egger\'s test, there was no significant publication bias under all comparisons in the present meta-analysis (data not shown).

4. Discussion {#sec4}
=============

Hormonal and reproductive factors have been implicated in the development of thyroid cancer, but the precise association and underlying molecular mechanisms have not yet been fully understood. A previous pooled analysis has investigated the association between female reproductive factors and thyroid cancer risk \[[@B39]\]. Unfortunately, only 17 epidemiological studies are included into the meta-analysis, which shows weak and equivocal association between some hormonal and menstrual cycle factors and thyroid cancer risk \[[@B39]\]. The present meta-analysis was based on 25 epidemiological studies on the association between hormonal and reproductive factors and thyroid cancer risk. No significant association was observed between thyroid cancer risk and common hormonal factors including oral contraceptive and hormone replacement therapy. Interestingly, older age at menopause might increase the risk of thyroid cancer, as suggested by the pooled RR in overall analysis (RR = 1.24, 95% CI 1.00--1.53, *P* = 0.049). Besides, longer duration of breast feeding was associated with moderately decreased risk of thyroid cancer, which had been suggested by the pooled analysis in cohort studies (RR = 0.7, 95% CI 0.51--0.95, *P* = 0.021). Moreover, the pooled result in hospital-based case-control studies revealed that parous women were more susceptible to thyroid cancer than nulliparous women (RR = 2.30, 95% CI 1.31--4.04, *P* = 0.004). Additionally, other reproductive factors including age at menarche, age at first birth, menopausal status, age at menopause, and breast feeding status did not modify the risk of thyroid cancer.

The risk of thyroid cancer in women increases at the time of puberty and declines after menopause \[[@B7], [@B40]\], supporting the hypothesis that menstrual cycle factors are involved in thyroid carcinogenesis. Elevated risk of thyroid cancer was related to the menopausal status when compared with premenopausal status \[[@B9]\]. Nonetheless, no significant association between the menopausal status, age at first birth, age at menarche, and age at menopause and thyroid cancer risk was observed \[[@B16], [@B18], [@B23], [@B27], [@B31]\]. It was worthwhile to note that menopausal females due to surgical factors were more susceptible to thyroid cancer compared with natural menopause ones \[[@B31]\], which might reflect enhanced medical surveillance of women who underwent surgical interventions for gynecological diseases symptoms. Similarly, we failed to identify any appreciable relationship of menstrual factors with thyroid cancer susceptibility. The discrepancies and underlying mechanisms need to be further elucidated by more relevant studies in the future.

It has been well established that estrogen receptors are found in thyroid cancer tissue and confer effects on different molecular signaling pathways involved in the growth and function of thyroid \[[@B5], [@B41], [@B42]\]. Estrogens and estrogen receptors signals exert promoting effect on the growth of thyroid gland by enhancing levels of TSH \[[@B7]\]. A number of studies have suggested some hormonal related factors, for instance, oral contraceptive and hormone replacement therapy, which played different roles in the thyroid cancer risk \[[@B8], [@B23], [@B27], [@B31]\]. Oral contraceptive seemed to play a protective role against thyroid cancer while an increased risk of thyroid cancer was found with the use of hormone replacement therapy demonstrated by Zamora-Ros et al. \[[@B31]\]. Similar findings were elucidated in a Caucasian cohort study \[[@B27]\]. Conversely, no modifying effects of oral contraceptive and hormone replacement therapy on the development of thyroid cancer were in another independent cohort study \[[@B8], [@B23]\]. The contradictory findings may be attributed to different study design, use of contraceptive and hormone replacement therapy, ethnicity, and adjusted or matching criteria in individual epidemiological studies. Our study showed no appreciable roles of hormonal factors in thyroid carcinogenesis, as suggested by both overall analysis and stratified analysis according to study design. More future studies are warranted to further estimate the association between hormonal-related factors and thyroid cancer risk.

The effect of breastfeeding on thyroid cancer risk is still not clear. Kabat and colleagues demonstrated that duration of breastfeeding did not alter the susceptibility to thyroid cancer \[[@B16]\]. However, Mack et al. provided the evidence that longer duration of breastfeeding was negatively associated with the risk of thyroid cancer risk, suggesting a protective role of breastfeeding in thyroid carcinogenesis \[[@B17]\]. Similarly, the pooled RRs in all cohort studies implicated that longer duration of breast feeding was associated with moderately reduced risk of thyroid cancer. Nevertheless, there was no significant relationship between breastfeeding status and thyroid carcinogenesis in pooled analyses of total studies and population-based case-control ones. Thus, the moderate association might be a chance resulting from potential bias in the present meta-analysis. To better understand the role of breastfeeding status in the thyroid cancer development, more relevant studies with high quality are warranted.

The status of parity conferred diverse effects on thyroid cancer risk in different populations. A recent study by Braganza et al. showed that parous women were at an elevated risk of thyroid cancer, as suggested by a recent epidemiological study \[[@B8]\]. Interestingly, for any given level of parity, there was about twofold increased risk of thyroid cancer among women with the age at last pregnancy larger than 30 years \[[@B19]\]. Unlike the findings mentioned above, no appreciable association was suggested between parity and the susceptibility to thyroid cancer among a Caucasian population \[[@B27]\]. In the current meta-analysis, significantly positive association was only demonstrated in the pooled analysis of two hospital-based case-control studies. Although age seemed to influence roles of reproductive factors in thyroid carcinogenesis, we failed to find appreciable association for age at first birth, age at menarche, and age at menopause. In addition, the pooled results, particularly in hospital-based case-control studies, must be interpreted with caution due to limited sample size and insufficient statistical power in current research.

Age is a main confounding factor for the association between hormonal and reproductive factors and thyroid cancer risk \[[@B19]\]. We failed to perform stratified analysis by age or other confounding factors, such as dosage and usage of hormonal drugs, the reason of menopause, number of live births, outcome of first pregnancy, and history of miscarriage, because of unavailable information about these items in single studies. Consequently, the association between hormonal and reproductive factors and thyroid cancer risk should be further investigated in view of above-mentioned confounding factors.

5. Conclusions {#sec5}
==============

The current meta-analysis suggests that older age at menopause and parity are associated with increased risk of thyroid cancer, while longer duration of breast feeding plays a protective role against this cancer. In addition, the precise association needs further investigation by more epidemiological studies with sufficient statistical power in the future.
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###### 

Characteristics of all epidemiological studies.

  First author                 Year   Origin              Time         Study design^§^   Hormonal or reproductive factors                                                                                                                                                         Adjusted or matching criteria
  ---------------------------- ------ ------------------- ------------ ----------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Högnäs \[[@B13]\]            2014   Finland             1974--2010   Cohort study      Parity                                                                                                                                                                                   Sex
                                                                                                                                                                                                                                                                                  
  Zamora-Ros \[[@B31]\]        2015   Europe              1992--2009   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, menopausal status, age at menopause, breastfeeding status, and duration of breastfeeding   Sex, center, and age at recruitment
                                                                                                                                                                                                                                                                                  
  Braganza \[[@B8]\]           2014   USA                 1993--2009   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, and age at menopause                                                                       Sex, education, race, marital status, family history of thyroid cancer, baseline body mass index, and smoking
                                                                                                                                                                                                                                                                                  
  Islami \[[@B15]\]            2013   Iran                2003--2007   PCC               Parity                                                                                                                                                                                   Age, sex, and neighborhood of residence
                                                                                                                                                                                                                                                                                  
  Kabat \[[@B16]\]             2012   USA                 1993--2011   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, age at menopause, and duration of breastfeeding                                            Sex, age, education, height, history of goiter/nodules, pack-years, and alcohol intake
                                                                                                                                                                                                                                                                                  
  Schonfeld \[[@B27]\]         2011   USA                 1995--2006   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, and age at menopause                                                                       Sex, smoking status, baseline body mass index, race, alcohol consumption, and education
                                                                                                                                                                                                                                                                                  
  Horn-Ross \[[@B14]\]         2011   USA                 1995--2008   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, and menopausal status                                                                      Sex, ethnicity, family history of thyroid cancer, time since last pregnancy, smoking, alcohol consumption, physical inactivity, height, adolescent cycle length, time to regular menstruation, and age at menarche
                                                                                                                                                                                                                                                                                  
  Meinhold \[[@B18]\]          2010   USA                 1983--2006   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, and menopausal status                                                                                          Sex, birth year, smoking status, body mass index, number of personal radiographs to the head or neck, and cumulative occupational radiation dose
                                                                                                                                                                                                                                                                                  
  Pham \[[@B23]\]              2009   Japan               1988--1997   Cohort study      Hormone replacement therapy, age at menarche, parity, age at first birth, and age at menopause                                                                                           Sex, age at baseline, body mass index, tobacco smoking status, education level, history of diabetes, and study area
                                                                                                                                                                                                                                                                                  
  Dorjgochoo \[[@B10]\]        2009   China               1996--2006   Cohort study      Oral contraceptive                                                                                                                                                                       Sex, education, age at menarche, number of live births, cumulative breast feeding months, body mass index, exercised regularly in past 5 years, smoking, menopausal status, first-degree family history of cancer, and other contraceptive methods
                                                                                                                                                                                                                                                                                  
  Hannibal \[[@B12]\]          2008   Denmark             1963--2000   Cohort study      Parity and age at first birth                                                                                                                                                            Sex, parity, age at cohort entry and calendar year of cohort entry, and age at first live birth
                                                                                                                                                                                                                                                                                  
  Brindel \[[@B9]\]            2008   France              1981--2004   PCC               Age at menarche, parity, age at first birth, menopausal status, age at menopause, breastfeeding status, and duration of breastfeeding                                                    Sex, educational level, height, body mass index, and interviewer
                                                                                                                                                                                                                                                                                  
  Wong \[[@B30]\]              2006   China               1989--1998   Cohort study      Oral contraceptive, age at menarche, parity, age at first birth, age at menopause, breastfeeding status, and duration of breastfeeding                                                   Sex, age, number of live births, and age at first live delivery
                                                                                                                                                                                                                                                                                  
  Truong \[[@B29]\]            2005   New Caledonia       1993--1999   PCC               Oral contraceptive, hormone replacement therapy, age at menarche, and parity                                                                                                             Sex, frequency, age, and residential area
                                                                                                                                                                                                                                                                                  
  Neale \[[@B21]\]             2005   Sweden              1961--1996   Cohort study      Age at first birth                                                                                                                                                                       Sex, date of birth of the mother, parity, and age at first birth
                                                                                                                                                                                                                                                                                  
  Navarro Silvera \[[@B20]\]   2005   Canada              1980--2000   Cohort study      Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, and menopausal status                                                                      Sex, age at first live birth, study center and randomization group, parity, and HRT use
                                                                                                                                                                                                                                                                                  
  Zivaljevic \[[@B32]\]        2003   Serbia              1996--2000   HCC               Parity                                                                                                                                                                                   Sex, age, place of residence, and time of hospitalization
                                                                                                                                                                                                                                                                                  
  Negri \[[@B22]\]             2002   Mixed               1974--1992   PCC               Age at menarche, parity, age at first birth, and menopausal status                                                                                                                       Sex, age, ethnicity, and study center
                                                                                                                                                                                                                                                                                  
  Memon \[[@B19]\]             2002   Middle East         1981--1999   PCC               Oral contraceptive, hormone replacement therapy, age at menarche, parity, age at first birth, and age at menopause                                                                       Sex, year of birth, nationality, and district of residence.
                                                                                                                                                                                                                                                                                  
  Sakoda \[[@B26]\]            2002   USA                 1992--1998   PCC               Age at menarche, menopausal status, and age at menopause                                                                                                                                 Sex, frequency, age, ethnicity, education level, history of goiter or nodules, history of radiation to the head or neck, and family history of proliferative thyroid disease
                                                                                                                                                                                                                                                                                  
  Rossing \[[@B24]\]           2000   USA                 1988--1994   PCC               Age at menarche, parity, age at first birth, and duration of breastfeeding                                                                                                               Sex, age, county of residence, race, and relative weight at age 10
                                                                                                                                                                                                                                                                                  
  Mack \[[@B17]\]              1999   USA                 1980--1983   PCC               Age at menarche, parity, age at first birth, menopausal status, breastfeeding status, and duration of breastfeeding                                                                      Sex, age, prior thyroid disease, and number of births
                                                                                                                                                                                                                                                                                  
  Takezaki \[[@B28]\]          1996   Japan               1988--1993   HCC               Age at menarche, parity, and age at first birth                                                                                                                                          Sex, age, and year of visit
                                                                                                                                                                                                                                                                                  
  Rossing \[[@B25]\]           1998   USA                 1988--1994   PCC               Oral contraceptive and hormone replacement therapy                                                                                                                                       Sex, age, county of residence, race, and relative weight at age 10
                                                                                                                                                                                                                                                                                  
  Galanti \[[@B11]\]           1996   Sweden and Norway   1985--1993   PCC               Oral contraceptive, hormone replacement therapy, parity, age at first birth, and age at menopause                                                                                        Sex, frequency, year and month of birth, type of menopause, and parity

  ^§^PCC: population-based case-control studies; HCC: hospital-based case-control studies.

###### 

Summary results for the association between hormonal and reproductive factors and thyroid cancer risk.

  Comparisons                    ^a^RR   ^b^95% CI      ^c^ *P* value   Tests for heterogeneity   
  ------------------------------ ------- ------------ ----------------- ------------------------- ---------
  All                                                                                              
   Oral contraceptive            0.94    0.85--1.04   0.215             36.0                      0.095
   Hormone replacement therapy   1.04    0.91--1.19   0.527             0                         0.520
   Age at menarche               1.08    0.97--1.19   0.142             0                         0.486
   Parity                        1.10    0.94--1.28   0.234             61.2                      \<0.001
   Age at first birth            1.07    0.95--2.20   0.255             14.8                      0.281
   Menopausal status             0.96    0.79--1.18   0.727             4.9                       0.394
   Age at menopause              1.24    1.00--1.53   0.049             26.4                      0.201
   Duration of breast feeding    0.84    0.65--1.08   0.178             38.3                      0.150
   Breast feeding                0.84    0.69--1.02   0.080             4.9                       0.368
  Cohort studies                                                                                   
   Oral contraceptive            0.96    0.86--1.07   0.448             39.5                      0.104
   Hormone replacement therapy   1.05    0.91--1.20   0.513             0                         0.439
   Age at menarche               1.01    0.90--1.14   0.808             16.1                      0.299
   Parity                        1.00    0.78--1.28   0.993             70.6                      \<0.001
   Age at first birth            1.04    0.92--1.18   0.530             0                         0.571
   Menopausal status             0.90    0.71--1.15   0.418             26.6                      0.252
   Age at menopause              1.3     1.04--1.63   0.022             2.5                       0.400
   Duration of breast feeding    0.70    0.51--0.95   0.021             0                         0.661
   Breast feeding                0.82    0.66--1.02   0.078             0                         0.442
  PCC                                                                                              
   Oral contraceptive            0.89    0.73--1.08   0.240             41.0                      0.166
   Hormone replacement therapy   1.01    0.68--1.50   0.962             6.0                       0.363
   Age at menarche               1.28    1.04--1.57   0.960             0                         0.937
   Parity                        1.00    0.93--1.07   0.960             21.6                      0.258
   Age at first birth            1.35    0.97--1.88   0.072             42.3                      0.123
   Menopausal status             1.10    0.78--1.57   0.577             0                         0.481
   Age at menopause              0.82    0.43--1.56   0.554             44.0                      0.147
   Duration of breast feeding    1.24    0.80--1.93   0.332             28.2                      0.248
   Breast feeding                0.92    0.60--1.41   0.699             57.6                      0.125
  HCC                                                                                              
   Parity                        2.30    1.31--4.04   0.004             0                         0.787

^a^RR: relative risk; ^b^95% CI: 95% confidence interval; ^c^ *P*: the value of *P* for pooled analysis; ^d^ *P*: the value of *P* for heterogeneity analysis.
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